Novel Withdrawal Symptoms of a Neonate Prenatally Exposed to a Fentanyl Analog.
Anticonvulsants
/ therapeutic use
Clonidine
/ therapeutic use
Female
Fentanyl
/ adverse effects
Humans
Infant, Newborn
Levetiracetam
/ therapeutic use
Methadone
/ therapeutic use
Myoclonus
/ chemically induced
Neonatal Abstinence Syndrome
/ drug therapy
Opioid-Related Disorders
/ complications
Parents
Pregnancy
Prenatal Exposure Delayed Effects
/ drug therapy
Treatment Outcome
Fentanyl
NAS
opioids
withdrawal
Journal
Journal of pediatric health care : official publication of National Association of Pediatric Nurse Associates & Practitioners
ISSN: 1532-656X
Titre abrégé: J Pediatr Health Care
Pays: United States
ID NLM: 8709735
Informations de publication
Date de publication:
Jan 2019
Jan 2019
Historique:
received:
11
04
2018
revised:
14
08
2018
accepted:
31
08
2018
pubmed:
13
11
2018
medline:
7
7
2020
entrez:
13
11
2018
Statut:
ppublish
Résumé
Neonatal abstinence syndrome (NAS) is a withdrawal syndrome observed in neonates exposed to drugs in utero, typically opioids, which is associated with symptoms affecting the central and autonomic nervous systems and the gastrointestinal system. West Virginia, particularly the southeastern region of the state, has remarkably higher rates of NAS than similar communities. Our facility is increasingly faced with complex cases of NAS caused by in utero exposure to multiple substances. We present a case report of a neonate born to a 25-year-old mother enrolled in a medication-assisted treatment program for substance use disorder who was noncompliant in prenatal care, using multiple substances throughout the pregnancy, including gabapentin and fentanyl. After birth, the neonate began to exhibit unusual withdrawal symptoms including arching, tongue thrusting, and irregular eye movements, which are typically associated with in utero gabapentin exposure. The parents denied consent to treat with gabapentin, the suggested management for these symptoms; thus, a treatment protocol for methadone and clonidine were followed. This case exemplifies the medical and social complexities involved in treating polysubstance exposure-associated NAS.
Identifiants
pubmed: 30415896
pii: S0891-5245(18)30204-9
doi: 10.1016/j.pedhc.2018.08.014
pii:
doi:
Substances chimiques
Anticonvulsants
0
Levetiracetam
44YRR34555
Clonidine
MN3L5RMN02
Methadone
UC6VBE7V1Z
Fentanyl
UF599785JZ
Types de publication
Case Reports
Journal Article
Langues
eng
Pagination
102-106Informations de copyright
Copyright © 2018 Elsevier Ltd. All rights reserved.